Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Study to Assess the Efficacy and Safety of 5% Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

NCT05848128 is registered in ClinicalTrials.gov with Mimetogen Pharmaceuticals USA, Inc. as lead sponsor.

NCT NCT05848128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05848128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Study to Assess the Efficacy and Safety of 5% Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Lead sponsor
Mimetogen Pharmaceuticals USA, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 28, 2023
Completion date
May 11, 2024
Enrollment
642 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye disease, dry eye syndromes, kerato conjunctivitis sicca